

Our Ref: 411/2021  
February 2021

## Re: Your request made under the Freedom of Information Act 2000

---

I am analysing the usage of anti-VEFG treatments for eye conditions. I would greatly appreciate if you could answer three questions:

- 1) For the 4-month period from September to December 2020, how many patients has your trust treated with the following anti-VEGF treatments:
  - Aflibercept **819**
  - Bevacizumab **18**
  - Brolucizumab **0**
  - Dexamethasone **5**
  - Fluocinolone acetonide **0**
  - Ranibizumab **50**
  
- 2) Within your trust how many intra-vitreous injections/implants of each of the following treatments have been used in the four-month period from September to December 2020:
  - Aflibercept **819**
  - Bevacizumab **18**
  - Brolucizumab **0**
  - Dexamethasone **5**
  - Fluocinolone acetonide **0**
  - Ranibizumab **50**
  
- 3) If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from September to December 2020 for each of the following conditions:

**Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**

Wet Age Related Macular Degeneration (wAMD)

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Ranibizumab

Diabetic Macular Oedema (DMO)

- Aflibercept
- Bevacizumab
- Dexamethasone
- Ranibizumab

Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)

- Aflibercept
- Bevacizumab
- Dexamethasone
- Ranibizumab